MACAU DAILY TIMES 澳門每日時報

Top Menu

  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia

Main Menu

  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia
logo
FOUNDER & PUBLISHER Kowie Geldenhuys
EDITOR-IN-CHIEF Paulo Coutinho
Macau,

MACAU DAILY TIMES 澳門每日時報

  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • CE confident non-gaming sectors can reach 60% of GDP in five years

  • Former prosecutor Kong Chi sentenced to 26 years in final appeal ruling

  • Electric vehicle charging fees cut 10% from January

  • Deals in Manila and Shenzhen, then a rare nuclear summit with Xi and Putin

  • Robert Pattinson is named the 7th Bond, taking over the role from Craig

  • Macau airport warns of possible flight adjustments during APEC Summit

World
Home›World›Europe approves Amgen’s first-in-class cholesterol drug

Europe approves Amgen’s first-in-class cholesterol drug

By -
Monday, July 27, 2015
97
0
 Statins have been the standard treatment for over 20 years

Statins have been the standard treatment for over 20 years

Amgen last week received European approval for its first-of-a-kind cholesterol drug that lowers levels of the artery-clogging substance more than older drugs that have been prescribed for decades.
The highly-anticipated decision introduces a new option for patients at risk for heart disease. But questions remain about the drug’s price — estimated by one analyst at about USD3,750 per year outside the U.S. — and its ability to reduce heart attacks and death in the long term.
The European Commission cleared Repatha for patients with dangerously high cholesterol levels, including those with inherited conditions that drive up levels of the wax-like substance. The injectable drug should be used by patients who cannot control their cholesterol with older statin drugs, or cannot tolerate them due to side effects, the group said.
Repatha is the first in a new class of medications that lower bad cholesterol more than statins, which have been the standard treatment for over 20 years.
Both drugs lower low-density lipoprotein, or LDL, cholesterol more powerfully and in a different ways than currently available drugs. They block a substance called PCSK9, which interferes with the liver’s ability to remove cholesterol from the blood. Adding the new drugs to older statins reduces LDL cholesterol by about 40 percent to 60 percent. Statins alone generally lower levels of bad cholesterol by about 25 to 35 percent.
But the prospect of introducing pricey, injectable drugs for one of the most common medical conditions in the world is drawing concerns from health insurers, providers and payers. Some analysts estimate the drugs could cost USD10,000 or more per year in the U.S.
A spokeswoman for Thousand Oaks, California-based Amgen declined to offer specifics on pricing Tuesday.
“Our prices are managed with consideration to competition, the local pricing and reimbursement environment and patient-cost sharing obligation, which vary considerably by country,” said Kristen Davis, in a statement.
Deutsche Bank analyst Robyn Karnauskas said it will take time to establish Repatha’s pricing in Europe, but she estimates the drug’s sales outside the U.S. will average about $3,750 per year. She expects European sales of the drug at $26 million this year, according to a research note.
Repatha and other PCSK9 drugs are expected to grow into blockbuster products, though prescribing may be limited at first by strict reimbursement in Europe and the U.S.
Doctors are awaiting studies of whether Repatha and similar drugs actually result in fewer heart attacks and deaths in patients with high cholesterol. Preliminary analyses published earlier this year suggest patients taking the new drugs had half the risk of dying or suffering a heart problem compared to those receiving older drugs. But definitive results aren’t expected until 2017 or later.
Global Data expects the entire class of PCSK9 drugs — including drugs from Sanofi and Pfizer — to generate sales of $17.8 billion by 2023.
Evercore ISI analyst Mark Schoenbaum noted the European Commission granted Repatha “a broad label,” encompassing many patients with various forms of high cholesterol. However, he said in a research note that “today’s decision has very little read across to the U.S.”, By Matthew Perrone in Washington, AP

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Print (Opens in new window) Print

Like this:

Like Loading…

Related

Previous Article

Deep-sea mining looms on horizon as UN ...

Next Article

Ask the Vet | Basic Dog Injury ...

Related articles More from author

  • World

    The Buzz | #MeToo: Bill Murray defends Hoffman over harassment allegations

    Friday, September 28, 2018
    By -
  • BuzzWorld

    On Beijing visit, Russian PM says pressure from West is strengthening ties with China

    Thursday, May 25, 2023
    By -
  • World

    Hoboken | Sinatra’s birthplace commemorates his 100th its way

    Tuesday, December 1, 2015
    By -
  • World

    Trump joins TikTok and calls it ‘an honor,’ although as president he tried to ban it

    Tuesday, June 4, 2024
    By -
  • World

    A diminished Biden heads to Peru, overshadowed by Xi

    Thursday, November 14, 2024
    By -
  • World

    World briefs

    Wednesday, November 19, 2014
    By -

Leave a reply Cancel reply

You must be logged in to post a comment.

  • HeadlinesMacau

    Taiwan closes borders to foreigners and transit passengers

  • Macau

    ETA requirement for Macau passport holders traveling to the UK

  • World

    Britain | Pro-EU side nervous as odds slashed on ‘leave’

DAILY EDITION

Tuesday, November 17, 2026 – edition no. 5076
Tuesday, November 17, 2026 – edition no. 5076

Greater Bay

MDT MACAU GRAND PRIX SPECIAL

November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« Oct    

Timeline

  • Tuesday, November 17, 2026

    CE confident non-gaming sectors can reach 60% of GDP in five years

  • Tuesday, November 17, 2026

    Former prosecutor Kong Chi sentenced to 26 years in final appeal ruling

  • Tuesday, November 17, 2026

    Electric vehicle charging fees cut 10% from January

  • Tuesday, November 17, 2026

    Deals in Manila and Shenzhen, then a rare nuclear summit with Xi and Putin

  • Tuesday, November 17, 2026

    Robert Pattinson is named the 7th Bond, taking over the role from Craig

  • Tuesday, November 17, 2026

    Macau airport warns of possible flight adjustments during APEC Summit

  • Tuesday, November 17, 2026

    Customs seizes 600,000 cigarettes on bridge

  • Tuesday, November 17, 2026

    IAS launches ‘Elderly Entrepreneurship’ funding scheme

  • Tuesday, November 17, 2026

    Gaming workforce falls to lowest level since records began

  • Tuesday, November 17, 2026

    Woman arrested after false robbery report

Extra Times

Extra TimesHeadlinesTaste of Edesia

Three chefs. One horizon. Six Michelin stars

There are moments when separate culinary philosophies align so precisely that the result transcends mere menu-making. At Chef Tam’s Seasons, Wynn Palace, three two-Michelin-starred titans—each ranked among Asia’s 50 Best ...
  • James Gray delivers a milestone crime drama in ‘Paper Tiger’

    By MDT/AP
    Friday, November 13, 2026
  • The Twelve25 × La Vie exchange

    By -
    Friday, November 13, 2026
  • A fiery milestone: Feng Wei Ju’s 20th anniversary tribute to Starworld Macau

    By Irene Sam, MDT
    Friday, November 6, 2026
  • In ‘I Play Rocky,’ a middleweight crowd-pleaser about the making of a classic

    By MDT/AP
    Friday, November 6, 2026
  • Recent

  • Popular

  • CE confident non-gaming sectors can reach 60% of GDP in five years

    By Renato Marques, MDT
    Tuesday, November 17, 2026
  • Former prosecutor Kong Chi sentenced to 26 years in final appeal ruling

    By Yuki Lei, MDT
    Tuesday, November 17, 2026
  • Electric vehicle charging fees cut 10% from January

    By Yuki Lei, MDT
    Tuesday, November 17, 2026
  • Deals in Manila and Shenzhen, then a rare nuclear summit with Xi and Putin

    By -
    Tuesday, November 17, 2026
  • Robert Pattinson is named the 7th Bond, taking over the role from Craig

    By -
    Tuesday, November 17, 2026
  • Macau airport warns of possible flight adjustments during APEC Summit

    By -
    Tuesday, November 17, 2026
  • Customs seizes 600,000 cigarettes on bridge

    By -
    Tuesday, November 17, 2026
  • Canidrome may have its days numbered, decision in ‘one or two months’

    By Paulo Coutinho, MDT
    Thursday, May 26, 2016
  • Animal Welfare | Macau: Anima slams Canidrome management for avoiding debate

    By -
    Wednesday, May 4, 2016
  • Editorial | Canidoomed

    By Paulo Coutinho, MDT
    Wednesday, June 1, 2016
  • Animal Welfare | Canidrome presented with ultimatum: close or move

    By Daniel Beitler, MDT
    Friday, July 22, 2016
  • Australia regulator cracks down on alleged exportation of dogs to Macau

    By Paulo Coutinho, MDT
    Friday, June 10, 2016
  • Animal rights | Canidrome: Anima in fresh airline negotiations as Canidrome closure looks more likely

    By Daniel Beitler, MDT
    Friday, May 27, 2016
  • USE OF ENGLISH IN MACAU | A ‘de facto’ official language

    By Catarina Pinto
    Monday, July 6, 2015
  • Contact our Administrator
  • Contact our Editor-in-Chief
  • Contacts
  • Our Team
  • Privacy Policy
  • Terms and Conditions
  • Editorial Statute
  • Code of Ethics
COPYRIGHT © MACAU DAILY TIMES 2008-2026. ALL RIGHTS RESERVED
MACAU DAILY TIMES
  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia
Loading Comments...

You must be logged in to post a comment.

%d